Rational basis for the combination of PCA3 and TMPRSS2:ERG gene fusion for prostate cancer diagnosis. (Q53801746)

19 May 2018

title

Rational basis for the combination of PCA3 and TMPRSS2:ERG gene fusion for prostate cancer diagnosis. (English)

1 reference

19 May 2018

1 reference

Grégoire Robert

1

1 reference

19 May 2018

Sander Jannink

2

1 reference

19 May 2018

Frank Smit

3

1 reference

19 May 2018

Tilly Aalders

4

1 reference

19 May 2018

Daphne Hessels

5

1 reference

19 May 2018

Ruben Cremers

6

1 reference

19 May 2018

Peter F Mulders

7

1 reference

19 May 2018

Jack A Schalken

8

1 reference

19 May 2018

publication date

5 June 2012

1 reference

19 May 2018

published in

The Prostate

1 reference

19 May 2018

volume

73

1 reference

19 May 2018

issue

2

1 reference

19 May 2018

page(s)

113-120

1 reference

19 May 2018

Urine biomarkers in prostate cancer

cites work

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22546

Molecular diagnosis of prostate cancer: PCA3 and TMPRSS2:ERG gene fusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22546

Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22546

External validation of urinary PCA3-based nomograms to individually predict prostate biopsy outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22546

Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22546

Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22546

ETS gene fusions in prostate cancer: from discovery to daily clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22546

Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22546

Management of rising prostate-specific antigen after a negative biopsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22546

Prostate cancer detection rate in patients with repeated extended 21-sample needle biopsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22546

Normalization of gene expression measurements in tumor tissues: comparison of 13 endogenous control genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22546

Is urinary sarcosine useful to identify patients with significant prostate cancer? The trials and tribulations of biomarker development

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22546

Phases of biomarker development for early detection of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22546

What is a biomarker? Research investments and lack of clinical integration necessitate a review of biomarker terminology and validation schema

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22546

Quantitative multi-gene expression profiling of primary prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22546

Predictive value of PCA3 in urinary sediments in determining clinico-pathological characteristics of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22546

PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of the dutasteride REDUCE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22546

Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22546

TMPRSS2-ERG gene fusion is associated with low Gleason scores and not with high-grade morphological features

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22546

Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22546

Molecular PCA3 diagnostics on prostatic fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22546

Predictors for biopsy outcome in the European Randomized Study of Screening for Prostate Cancer (Rotterdam region).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22546

TMPRSS2-ERG Fusion Prostate Cancer: An Early Molecular Event Associated With Invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22546

Diversity of TMPRSS2-ERG fusion transcripts in the human prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22546

21 January 2018

Identifiers

DOI

10.1002/PROS.22546

1 reference

19 May 2018

PubMed ID

22674214

1 reference

19 May 2018